{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:49:14Z","timestamp":1788580154400,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejpb.2026.115096","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:56:30Z","timestamp":1778025390000},"page":"115096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of levothyroxine sodium pediatric oral solution driven by STEP database: Stability study and degradation products by LC-MS"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1760-1308","authenticated-orcid":false,"given":"Brendha Lang","family":"Camboim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Silveira","family":"Bersagui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia Helena","family":"de Oliveira Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-2297","authenticated-orcid":false,"given":"M\u00e1rcio Vin\u00edcius","family":"Ayres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Sebastian","family":"Loureiro Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ssia Virginia","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115096_b0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/01.med.0000433063.78799.c2","article-title":"Hypothyroidism in the Newborn Period","volume":"20","author":"Wassner","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115096_b0010","first-page":"128","article-title":"Pharmacological aspects of levothyroxin sodium: a brief review","volume":"23","author":"Geronimo","year":"2018","journal-title":"Brazilian J. Surg. Clin. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115096_b0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5603\/EP.a2022.0078","article-title":"Liquid levothyroxine improves thyroid control in patients with different hypothyroidism aetiology and variable adherence - case series and review","volume":"73","author":"Rucha\u0142a","year":"2022","journal-title":"Endokrynol. Pol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115096_b0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/endrev\/bnac030","article-title":"Levothyroxine: conventional and novel drug delivery formulations","volume":"44","author":"Liu","year":"2023","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115096_b0025","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060420","article-title":"Guidance for the clinician in rendering pediatric care congenital hypothyroidism: screening and management","volume":"151","author":"Rose","year":"2023","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115096_b0030","first-page":"93","article-title":"New formulations of levothyroxine in the treatment of hypothyroidism Endocrinologia","volume":"71","author":"Iglesias","year":"2024","journal-title":"Diabet. Y Nutricion."},{"issue":"133","key":"10.1016\/j.ejpb.2026.115096_b0035","article-title":"Tireoidite de Hashimoto: aspectos fisiopatol\u00f3gicos, diagn\u00f3sticos, terap\u00eauticos e impacto na qualidade de vida","volume":"28","author":"Antero","year":"2024","journal-title":"Revista FT."},{"issue":"JUL","key":"10.1016\/j.ejpb.2026.115096_b0040","article-title":"Refractory hypothyroidism due to improper storage of levothyroxine tablets","volume":"8","author":"Benvenga","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115096_b0045","first-page":"398","article-title":"Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products","volume":"9","author":"Glass","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115096_b0050","doi-asserted-by":"crossref","unstructured":"de Vasconcelos JC, Hamer ER. Indicadores de qualidade para otimiza\u00e7\u00e3o da qualidade em farm\u00e1cia hospitalar. Revista de Pesquisa Cuidado \u00e9 Fundamental Online. 2023;15:1-7. doi:10.9789\/2175-5361.rpcfo.v15.12734.","DOI":"10.9789\/2175-5361.rpcfo.v15.12734"},{"key":"10.1016\/j.ejpb.2026.115096_b0055","unstructured":"WHO. The International Pharmacopoeia. 12th ed. World Health Organization Department of Essential Medicines and Health Products; 2025. https:\/\/digicollections.net\/phint\/pdf\/b\/6.1.210.Levothyroxine-sodium-(Levothyroxinum-natricum).pdf. Accessed October 5, 2025."},{"key":"10.1016\/j.ejpb.2026.115096_b0060","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.3390\/ijms24108822","article-title":"Ionic levothyroxine formulations: synthesis, bioavailability, and cytotoxicity studies","volume":"24","author":"Barreira","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115096_b0065","unstructured":"EMA. Guideline on Pharmaceutical Development of Medicines for Paediatric Use.; 2013. https:\/\/www.ema.europa.eu\/en\/pharmaceutical-development-medicines-paediatric-use-scientific-guideline. Accessed October 6, 2025."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115096_b0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2015.0422","article-title":"A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study","volume":"26","author":"Cappelli","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115096_b0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/thy.2020.0515","article-title":"New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat?","volume":"31","author":"Nagy","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.ejpb.2026.115096_b0080","doi-asserted-by":"crossref","unstructured":"Balsan ME, Gobetti C, Garcia CV. Medicamentos off-label e n\u00e3o licenciados no \u00e2mbito pedi\u00e1trico: uma revis\u00e3o descritiva dos \u00faltimos dez anos. Clinical & Biomedical Research. Published online March 3, 2022. doi:10.22491\/2357-9730.125057.","DOI":"10.22491\/2357-9730.125057"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115096_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010119","article-title":"Potentially harmful excipients: state of the art for oral liquid forms used in neonatology and pediatrics units","volume":"16","author":"Bobillot","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115096_b0090","doi-asserted-by":"crossref","unstructured":"Boulton. Stability of an Extemporaneously Compounded Levothyroxine Sodium Oral Liquid.; 1996. https:\/\/academic.oup.com\/ajhp\/article-abstract\/53\/10\/1157\/5094131.","DOI":"10.1093\/ajhp\/53.10.1157"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115096_b0095","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.japh.2020.05.014","article-title":"Stability and consistency of compounded oral liquid levothyroxine formulations","volume":"60","author":"Meyer","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ejpb.2026.115096_b0100","unstructured":"EuPFI. STEP database. European Paediatric Formulation Initiative. Published 2017. https:\/\/step-db.ucl.ac.uk\/eupfi\/appDirectLink.do?appFlag=login. Accessed September 11, 2025."},{"key":"10.1016\/j.ejpb.2026.115096_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114447","article-title":"Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms \u2013 Part 2","volume":"203","author":"Agrawal","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115096_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114458","article-title":"Selecting appropriate excipients for paediatric dosage form \u2212 paediatric excipients risk assessment (PERA) framework \u2013 Part 1","volume":"203","author":"Salunke","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115096_b0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijpharm.2017.07.042","article-title":"Challenges and strategies to facilitate formulation development of pediatric drug products: safety qualification of excipients","volume":"536","author":"Buckley","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115096_b0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijpharm.2015.06.016","article-title":"The STEP database through the end-users eyes\u2014USABILITY STUDY","volume":"492","author":"Salunke","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115096_b0125","unstructured":"United States Pharmacopeia. Levothyroxine Sodium.; 2019."},{"key":"10.1016\/j.ejpb.2026.115096_b0130","unstructured":"ICH. Guideline on Validation of Analytical Procedures Q2(R2).; 2023. https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline. Accessed August 24, 2025."},{"key":"10.1016\/j.ejpb.2026.115096_b0135","unstructured":"iBtek (2024) \u201cManual MK5.\u201d Available at: https:\/\/ibtek.com.br\/mk5\/. Accessed January 6 2026."},{"key":"10.1016\/j.ejpb.2026.115096_b0140","unstructured":"British Pharmacopoeia. Levothyroxine Oral Solution. Volume III. 2014."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115096_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030387","article-title":"Excipients in the paediatric population: a review","volume":"13","author":"Rouaz","year":"2021","journal-title":"Pharmaceutics."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115096_b0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.xphs.2020.09.054","article-title":"Detection and characterization of an unknown impurity in levothyroxine oral solution product: implications for formulation development and storage","volume":"110","author":"Sreeramoju","year":"2021","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejpb.2026.115096_b0155","unstructured":"United States Pharmacopeia (2020) Levothyroxine Sodium Compounded Oral Suspension. Available at: https:\/\/online.uspnf.com\/uspnf\/document\/2_GUID-D0EAFE6A-2698-4886-8019-487A35C67E4D_10101_en-US?source=Search%20Results&highlight=levothyroxine Accessed: November 4, 2025."},{"key":"10.1016\/j.ejpb.2026.115096_b0160","series-title":"Pharmaceutical preformulation and formulation: a practical guide from candidate drug selection to commercial dosage form","first-page":"541","author":"Gibson","year":"2009"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115096_b0165","first-page":"1","article-title":"Neonates exposed to excipients:concern about safety","volume":"7","author":"Cuzzolin","year":"2018","journal-title":"J. Pediat. Neonatal Ind. Med."},{"key":"10.1016\/j.ejpb.2026.115096_b0170","unstructured":"EMA. Reflection Paper on the Use of Methyl-and Propylparaben as Excipients in Human Medicinal Products for Oral Use.; 2015. https:\/\/www.ema.europa.eu\/en\/use-methyl-propylparaben-excipients-human-medicinal-products-oral-use-scientific-guideline. Accessed October 6, 2025."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115096_b0175","article-title":"Stability of paracetamol instant jelly for reconstitution: impact of packaging, temperature and humidity","volume":"8","author":"Almurisi","year":"2022","journal-title":"Gels."},{"key":"10.1016\/j.ejpb.2026.115096_b0180","unstructured":"Opuspac. Embalagens Unidose Opuspac. Published 2025. https:\/\/opuspac.com\/materiais\/embalagens-para-unitarizacao\/. Accessed September 11, 2025."},{"key":"10.1016\/j.ejpb.2026.115096_b0185","doi-asserted-by":"crossref","unstructured":"Soares JVS, Prado WC, Da Costa ACP, E Silva AK da S, Pereira CVL, Bonatto J de A, et al. Determina\u00e7\u00e3o de par\u00e2metros de qualidade de embalagens metalizadas flex\u00edveis para alimentos. Brazilian Journal of Development. 2023;9(3):9124-9138. doi:10.34117\/bjdv9n3-018.","DOI":"10.34117\/bjdv9n3-018"},{"key":"10.1016\/j.ejpb.2026.115096_b0190","article-title":"Biaxial stretching of Film","author":"DeMeuse","year":"2011","journal-title":"Woodhead Publ."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115096_b0195","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1590\/S1516-14392011005000080","article-title":"Degradation study of polypropylene (PP) and Bioriented polypropylene (BOPP) in the environment","volume":"14","author":"Longo","year":"2011","journal-title":"Materials Research."},{"key":"10.1016\/j.ejpb.2026.115096_b0200","first-page":"816","article-title":"Ecodesign approach for pharmaceutical packaging based on Life Cycle Assessment","author":"Bassani","year":"2022","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ejpb.2026.115096_b0205","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0731-7085(01)00370-3","article-title":"Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection","volume":"25","author":"Kazemifard","year":"2001","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115096_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1039\/b307970h","article-title":"Determination of levothyroxine and its degradation products in pharmaceutical tablets by HPLC-UV-ICP-MS","volume":"19","author":"Kannamkumarath","year":"2004","journal-title":"J. Anal. Atomic Spectrom."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115096_b0215","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1021\/ac303404e","article-title":"Investigation of reaction mechanisms of drug degradation in the solid state: a kinetic study implementing ultrahigh-performance liquid chromatography and high-resolution mass spectrometry for thermally stressed thyroxine","volume":"85","author":"Neu","year":"2013","journal-title":"Analyt. Chem."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:12:46Z","timestamp":1783116766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0939641126001177"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115096","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of levothyroxine sodium pediatric oral solution driven by STEP database: Stability study and degradation products by LC-MS","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115096"}}